Passive Music Listening in Acute Cerebrovascular Disease
NCT06743412, Not applicable, Completed, IRCCS Ospedale San Raffaele
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Passive Music Listening in Acute Cerebrovascular Disease | ClinicalTrials.gov |
| NCT number | NCT06743412 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 150 participants, actual | ClinicalTrials.gov |
| Lead sponsor | IRCCS Ospedale San Raffaele | ClinicalTrials.gov |
| Conditions | Acute Stroke | ClinicalTrials.gov |
| Interventions | Regular music listening | ClinicalTrials.gov |
| First posted | 2024-12-19 | ClinicalTrials.gov |
| Last updated | 2026-03-17 | ClinicalTrials.gov |
Registered outcomes 17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Improvement in anxiety/depression levels (HADS score) between baseline and discharge. | Baseline vs. discharge (up to 30 days) | Hospital Anxiety and Depression Scale (HADS), total score ranges between 0-21, with higher values indicating higher levels of anxiety/depression. | ClinicalTrials.gov |
| Primary | Improvement in the patient's perception of overall health status between baseline and discharge (EQ-VAS). | Baseline vs. discharge (up to 30 days) | EuroQol-visual analogue scales (EQ-VAS). The EQ-VAS is a vertical visual analogue scale that takes values between 100 (best imaginable health) and 0 (worst imaginable health), on which patients provide a global assessment of their health. | ClinicalTrials.gov |
| Primary | Feasibility and acceptability during hospitalization (Percentage of patients who refuse to participate in the study) | Baseline | Percentage of patients who refuse to participate in the study | ClinicalTrials.gov |
| Primary | Feasibility and acceptability during hospitalization (percentage of drop-outs). | Baseline-discharge (up to 30 days) | percentage of drop-outs. | ClinicalTrials.gov |
| Primary | Feasibility and acceptability during hospitalization (percentage of days and total hours of music listening during the hospitalization phase). | Baseline-discharge (up to 30 days) | percentage of days and total hours of music listening during the hospitalization phase. | ClinicalTrials.gov |
| Secondary | Improvement in anxiety/depression levels (HADS score) | 3 months (+/- 1 month) follow-up visit | Hospital Anxiety and Depression Scale (HADS), total score ranges between 0-21, with higher values indicating higher levels of anxiety/depression. | ClinicalTrials.gov |
| Secondary | Improvement in the patient's perception of overall health status (EQ-VAS). | 3 months (+/- 1 month) follow-up visit | EuroQol-visual analogue scales (EQ-VAS). The EQ-VAS is a vertical visual analogue scale that takes values between 100 (best imaginable health) and 0 (worst imaginable health), on which patients provide a global assessment of their health. | ClinicalTrials.gov |
| Secondary | Feasibility and acceptability (percentage of drop-outs). | 3 months (+/- 1 month) follow-up visit | percentage of drop-outs | ClinicalTrials.gov |
| Secondary | Evaluation of cognitive functions through MoCA test | Basline vs. discharge (up to 30 days) vs. 3 months (+/- 1 month) follow-up visit | MoCA (Montreal Cognitive Assessment or The MoCA Test) is a tool for early detection of mild cognitive impairment; total score ranges between 0 and 30, with lower values indicating increasing cognitive impairment. | ClinicalTrials.gov |
| Secondary | Evaluation of cognitive functions through Stroop test | Basline vs. discharge (up to 30 days) vs. 3 months (+/- 1 month) follow-up visit | The time interference score and the error interference score will be measured; according to normative data, the scores will be converted in equivalent scores from 0 to 4 with lower values indicating higher level of impairment. | ClinicalTrials.gov |
| Secondary | Evaluation of cognitive functions through delayed story recall | Basline vs. discharge (up to 30 days) vs. 3 months (+/- 1 month) follow-up visit | The raw score will be converted, according to normative data, to an equivalent score between 0 and 4 with lower values indicating more impairment. | ClinicalTrials.gov |
| Secondary | Patient perception of health status related to mobility, usual activities, anxiety, depression, and pain (EQ-5D-3L Italian version). | Baseline vs. discharge (up to 30 days) vs. 3 months (+/- 1 month) follow-up | The EQ-5D-3L (European Quality of Life 5 Dimensions 3 Level Version) is a Patient Reported Outcomes (PRO) which examines five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The questionnaire produces a 5-digit health state profile that represents the level of reported problems on each of the five dimensions of health. EQ-5D 5-digit health state is subsequently converted into a single index value, according to normative, which reflects the health state. | ClinicalTrials.gov |
| Secondary | Patient perception of sleep quality (ISI insomnia severity index, Italian version). | Baseline vs. discharge (up to 30 days) vs. 3 months (+/- 1 month) follow-up visit | The total score ranges from 0 to 28, with higher score indicating greater insomnia severity. | ClinicalTrials.gov |
| Secondary | Blood pressure, pre- and post-listening. | hospitalization phase (discharge-baseline, up to 30 days) | Blood pressure, pre- and post-listening to music. Measure unit: mmHg | ClinicalTrials.gov |
| Secondary | Daily average number of administrations of sedatives, anxiolytics, and antidepressants. | hospitalization phase (discharge-baseline, up to 30 days) | ClinicalTrials.gov | |
| Secondary | Heart rate, pre- and post-listening. | hospitalization phase (discharge-baseline, up to 30 days) | Heart rate, pre- and post-listening to music. Measure unit: beats/min. | ClinicalTrials.gov |
| Secondary | Feasibility and acceptability (percentage of days and total hours of music listening). | 3 months (+/- 1 month) follow-up visit | percentage of days and total hours of music listening. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Short Story Recall | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)